Chemclin Diagnostics Co., Ltd.

SHSE:688468 Stock Report

Market Cap: CN¥2.6b

Chemclin Diagnostics Past Earnings Performance

Past criteria checks 2/6

Chemclin Diagnostics has been growing earnings at an average annual rate of 1.8%, while the Medical Equipment industry saw earnings growing at 6.1% annually. Revenues have been declining at an average rate of 0.8% per year. Chemclin Diagnostics's return on equity is 9.9%, and it has net margins of 31.4%.

Key information

1.8%

Earnings growth rate

-8.3%

EPS growth rate

Medical Equipment Industry Growth16.0%
Revenue growth rate-0.8%
Return on equity9.9%
Net Margin31.4%
Next Earnings Update29 Apr 2025

Recent past performance updates

Weak Statutory Earnings May Not Tell The Whole Story For Chemclin Diagnostics (SHSE:688468)

Nov 06
Weak Statutory Earnings May Not Tell The Whole Story For Chemclin Diagnostics (SHSE:688468)

Concerns Surrounding Chemclin Diagnostics' (SHSE:688468) Performance

May 06
Concerns Surrounding Chemclin Diagnostics' (SHSE:688468) Performance

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Chemclin Diagnostics (SHSE:688468)

Nov 06
Weak Statutory Earnings May Not Tell The Whole Story For Chemclin Diagnostics (SHSE:688468)

Little Excitement Around Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Earnings

Sep 28
Little Excitement Around Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Earnings

Concerns Surrounding Chemclin Diagnostics' (SHSE:688468) Performance

May 06
Concerns Surrounding Chemclin Diagnostics' (SHSE:688468) Performance

Little Excitement Around Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Earnings

Apr 30
Little Excitement Around Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Earnings

Chemclin Diagnostics (SHSE:688468) Shareholders Will Want The ROCE Trajectory To Continue

Mar 27
Chemclin Diagnostics (SHSE:688468) Shareholders Will Want The ROCE Trajectory To Continue

Revenue & Expenses Breakdown

How Chemclin Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688468 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2444413914067
30 Jun 2445214713762
31 Mar 2445615113967
31 Dec 2344514713365
30 Sep 2345115512864
30 Jun 2346116013368
31 Mar 2344514812967
31 Dec 2246515313568
30 Sep 2247515313670
30 Jun 2245714213668
31 Mar 2247114414271
31 Dec 2147114314367
30 Sep 2147814814959
30 Jun 2150415614864
31 Mar 2147914413958
31 Dec 2041811712954
31 Dec 1945514114155
31 Dec 18366-42463350
31 Dec 17319-43562131

Quality Earnings: 688468 has high quality earnings.

Growing Profit Margin: 688468's current net profit margins (31.4%) are lower than last year (34.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688468 has become profitable over the past 5 years, growing earnings by 1.8% per year.

Accelerating Growth: 688468's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 688468 had negative earnings growth (-9.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (-8.8%).


Return on Equity

High ROE: 688468's Return on Equity (9.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 00:49
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chemclin Diagnostics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution